| Autor: |
Milena Matuszczak, Adam Kiljańczyk, Wojciech Marciniak, Róża Derkacz, Klaudia Stempa, Piotr Baszuk, Marta Bryśkiewicz, Cezary Cybulski, Tadeusz Dębniak, Gronwald Jacek, Tomasz Huzarski, Marcin Lener, Anna Jakubowska, Sandra Pietrzak, Marek Szwiec, Małgorzata Stawicka-Niełacna, Dariusz Godlewski, Artur Prusaczyk, Andrzej Jasiewicz, Tomasz Kluz, Joanna Tomiczek-Szwiec, Ewa Kilar-Kobierzycka, Monika Siołek, Renata Posmyk, Joanna Jarkiewicz-Tretyn, Rodney Scott, Steven Narod, Jan Lubiński |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Hereditary Cancer in Clinical Practice, Vol 22, Iss 1, Pp 1-7 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
1897-4287 |
| DOI: |
10.1186/s13053-024-00291-7 |
| Popis: |
Abstract Objective To investigate whether Molybdenum blood level is a marker of cancer risk on BRCA1 carriers. Methods A prospective cohort study was conducted among 989 initially unaffected women with a BRCA1 mutation. Blood samples were collected to measure molybdenum levels, and participants were followed for an average of 7.5 years. Cox proportional hazards models were used to assess the association between blood molybdenum levels and cancer incidence, adjusting for potential confounders. Results High blood molybdenum levels (> 0.70 µg/L) were significantly associated with an increased risk of developing ovarian cancer (HR = 5.55; 95%CI: 1.59–19.4; p = 0.007) and any cancer (HR = 1.74; 95%CI: 1.17–2.61; p = 0.007) but not breast cancer (HR = 1.46, CI = 0.91–2.33; p = 0.12). The cumulative incidence of ovarian cancer at ten years was 1.2% for the lowest molybdenum tertile, 4.2% for the middle tertile, and 8.7% for the highest tertile. Conclusion Elevated blood molybdenum levels are associated with an increased risk of ovarian cancer on BRCA1 mutation carriers. Lowering molybdenum levels may potentially reduce cancer risk in this population, and high molybdenum levels could serve as a marker for considering preventive oophorectomy in BRCA1 carriers. Further research is warranted to confirm these findings and explore interventions targeting molybdenum levels as a preventive measure for ovarian cancer in BRCA1 mutation carriers. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
